| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.954009 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20250822151545 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn |||||||| |
|---|
| 008 | 250812s2024 oncd os f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 041 | 0 |aeng|afre |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH82-58/2024-PDF |
|---|
| 100 | 1 |aGaudette, EĢtienne, |d1953- |eauthor. |
|---|
| 245 | 10|aCost-effectiveness of the top 100 drugs by public spending in Canada, 2015–2021 : |ba repeated cross-sectional study / |cÉtienne Gaudette, Shirin Rizzardo, Yvonne Zhang, Mina Tadrous, and Kevin R. Pothier = Rapport coût-efficacité des 100 médicaments représentant les plus grandes dépenses des régimes publics au Canada, 2015-2021 : une étude transversale répétée / Étienne Gaudette, Shirin Rizzardo, Yvonne Zhang, Mina Tadrous et Kevin R. Pothier. |
|---|
| 246 | 11|aRapport coût-efficacité des 100 médicaments représentant les plus grandes dépenses des régimes publics au Canada, 2015-2021 : |bune étude transversale répétée |
|---|
| 264 | 1|a[Ottawa] : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |c[2024] |
|---|
| 300 | |a1 online resource (1 unnumbered page) : |bgraphs |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"NPDUIS, National Prescription Drug Utilization Information System, "Supporting health care decision making in Canada" = SNIUMP, Le Système national d'information sur l'utilisation des médicaments prescrits, « Appuyer les décisions en matière des soins de santé au Canada »" |
|---|
| 520 | |a"To assess the distribution and spending by cost-effectiveness category amongst those drugs with the highest public spending levels in Canada. The share of public pharmaceutical spending allocated to cost-effective and cost-ineffective drugs was estimated using Canadian Agency for Drugs and Technologies in Health (CADTH) cost-effectiveness assessments and Canadian public plan spending data from six provinces"--Introduction, page [1]. |
|---|
| 546 | |aText in English and French. |
|---|
| 650 | 0|aDrugs|zCanada|vStatistics. |
|---|
| 650 | 0|aPharmaceutical policy|zCanada|vStatistics. |
|---|
| 650 | 0|aExpenditures, Public|vStatistics. |
|---|
| 651 | 0|aCanada|xAppropriations and expenditures|vStatistics. |
|---|
| 655 | 7|aStatistics|2lcgft |
|---|
| 710 | 1 |aCanada. |bPatented Medicine Prices Review Board, |eissuing body. |
|---|
| 788 | |tCost-effectiveness of the top 100 drugs by public spending in Canada, 2015–2021 : |efre|w(CaOODSP)9.954008 |
|---|
| 856 | 40|qPDF|s441 KB|uhttps://publications.gc.ca/collections/collection_2025/cepmb-pmprb/H82-58-2024.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/posters/cost-effectiveness-100-drugs.html |
|---|